It was in 2013 — before we formed as a company — that our scientists began working with researchers from AstraZeneca. Now, more than five years later, we have announced a strategic partnership with our long-time collaborator that will make AstraZeneca the first pharmaceutical company to embed our Human Emulation System within their laboratories. This announcement marks a significant milestone for both organizations as we work together to gain new insights into disease mechanisms using our Organs-on-Chips technology.
As part of this agreement, both organizations will exchange scientists, co-locating them in our headquarters in Boston and in AstraZeneca’s IMED Biotech Unit in Cambridge, England. These exchanges will help us pursue our approach of optimizing our system through real-world collaborative research with a leader in the pharmaceutical industry.